We demonstrate that ERG protein is an independent prognostic biomarker for prostate cancer patients not receiving adjuvant treatment and with undetectable PSA after RP, and that ERG is of particular importance for Grade Group 4–5 patients. The gene discussed is ERG; the disease is prostate cancer.